Cookson Peirce & Co. Inc. Sells 14,346 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Cookson Peirce & Co. Inc. reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,249,126 shares of the company’s stock after selling 14,346 shares during the quarter. Teva Pharmaceutical Industries makes up about 1.2% of Cookson Peirce & Co. Inc.’s holdings, making the stock its 26th biggest holding. Cookson Peirce & Co. Inc.’s holdings in Teva Pharmaceutical Industries were worth $27,531,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Diversify Advisory Services LLC increased its position in shares of Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after buying an additional 496 shares during the period. Sanctuary Advisors LLC lifted its holdings in Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after buying an additional 664 shares during the period. Metis Global Partners LLC boosted its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after acquiring an additional 860 shares in the last quarter. DGS Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after acquiring an additional 872 shares during the period. Finally, Williamson Legacy Group LLC raised its position in shares of Teva Pharmaceutical Industries by 1.7% in the 4th quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company’s stock worth $1,274,000 after acquiring an additional 979 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TEVA shares. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $15.63 on Wednesday. The company has a market capitalization of $17.72 billion, a PE ratio of -10.78, a PEG ratio of 1.44 and a beta of 0.71. The business has a fifty day moving average price of $19.28 and a 200-day moving average price of $18.44. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.